Pharmacodynamics and Proposed Mechanism of Therapeutic Action and Host Toxicity of 9-β-D-Arabinofuranosyl-2-Fluoroadenine Monophosphate (F-araAMP) in P388 Murine Leukemia-Bearing Mice

References

• Brockman R W, Schabel F M, Jr, Montgomery J A. Biologic activity of 9-β-D-arabinofuranosyl-2-fluoroadenine, a metabolically stable analog of 9-β-D-arabinofuranosyladenine. Biochem Pharmacol 1977; 26: 2193–2196
   PubMed Web of Science ®Google Scholar
• Monntgomery J A, HewsonK. Nucleosides of 2-fluoroadenine. J Med Chem 1969; 12: 498–504
   PubMed Web of Science ®Google Scholar
• Brockman R W, Cheng Y-C, Schabel F M, Jr, Montgomery J A. Metabolism and chemotherapeutic activity of 9-β-D-arabino-furanosyl-2-fluoroadenine, against murine leukemia L1210 and evidence for its phosphorylation by deoxycytidine kinase. Cancer Res 1980; 40: 3610–3615
   PubMed Web of Science ®Google Scholar
• Avramis V I, Plunkett W. Metabolism and therapeutic efficacy of 9-β-D-arabinofuranosyl-2-fluoroadenine against murine leukemia P388. Cancer Res 1982; 42: 2587–2591
   PubMed Web of Science ®Google Scholar
• Barrueco J R, Jacobsen D M, Chang C-H, et al. Proposed mechanism of therapeutic selectivity for 9-β-D-arabinofuranosyl-2-fluoro-adenine against murine leukemia based upon lower capacities for transport and phosphorylation in proliferative intestinal epithelium compared to tumor cells. Cancer Res 1987; 47: 700–706
   PubMed Web of Science ®Google Scholar
• Avramis V I, Plunkett W. Metabolism of 9-β-D-arabinosyl-2-fluoroadenine-5′-phosphate by mice bearing P388 leukemia. Cancer Drug Del 1983; 1: 1–10
   PubMedGoogle Scholar
• Chello P L, Sirotnak F M, Dorick D M, et al. Initial rate kinetics and evidence for duality of mediated transport of adenosine, related purine nucleosides, and nucleoside analogues in L1210 cells. Cancer Res 1983; 43: 97–103
   PubMed Web of Science ®Google Scholar
• Paterson A RP. Transport of nucleosides and nucleoside analogs by animal cells. Molecular Actions and Targets for Cancer Chemotherapy Agents, A C Sartorelli, J S Lazo, J R Bertino. Academic Press, Inc., New York 1981; 213–226
   Google Scholar
• Plagemann P GW, Marz R, Wohlhueter R M. Transport and metabolism of deoxycytidine and l-β-D-arabinofuranosylcytosine into cultured Novikoff rat hepatoma cells, relationship to phosphorylation and regulation of triphosphate synthesis. Cancer Res 1978; 38: 978–989
   PubMed Web of Science ®Google Scholar
• Plagemann P GW, Marz R, Wohlhueter R M. Uridine transport in Novikoff rat hepatoma cells and other cell lines and its relationship to uridine phosphorylation and phosphorolysis. J Cell Physiol 1978; 97: 49–72
   PubMed Web of Science ®Google Scholar
• Plagemann P GW, Wohlhueter R M. Permeation of nucleosides, nucleic acids, bases and nucleotides in animal cells. Curr Top Membr Transp 1980; 14: 226–313
   Google Scholar
• Koren R, Shohami E, Yeroushalmi S A. A kinetic analysis of the uptake of cytosine-β-D-arabinoside by rat-B77 cells. Differentiation between transport and phosphorylation. Eur J Biochem 1979; 95: 333–339
   PubMedGoogle Scholar
• Cadman E, Eiferman F, Heimer R, David L. Pyrazofurin enhancement of 5-azacytidine antitumor activity in L51784 and human leukemia cells. Cancer Res 1978; 38: 4610–4617
   PubMed Web of Science ®Google Scholar
• Cass C E, Selner M, Phllips R J. Resistance to 9-β-D-arabinofura-nosyladenine in cultured leukemia L1210 cells. Cancer Res 1983; 43: 4791–4798
   PubMed Web of Science ®Google Scholar
• Kessel D, Shurin S B. Transport of two non-metabolized nucleosides, deoxycytidine and cytosine arabinoside, in a sub-line of the L1210 murine leukemia. Biochim Biophys Acta 1968; 163: 179–187
   PubMed Web of Science ®Google Scholar
• Wiley J S, Jones S P, Sawyer W H, Paterson A RP. Cytosine arabinoside influx and nucleoside transport sites in acute leukemia. J Clin Invest 1982; 69: 479–489
   PubMed Web of Science ®Google Scholar
• Sirotnak F M, Chello P L, Dorick D M, Montgomery J A. Specificity of systems mediating transport of adenosine, 9-β-D-arabino-furanosyl-2-fluoroadenine, and other purine nucleoside analogue in L1210 cells. Cancer Res 1983; 43: 104–109
   PubMed Web of Science ®Google Scholar
• Plunkett W, Chubb S, Alexander L, Montgomery J A. Comparison of the toxicity and metabolism of 9-β-D-arabinofuranosyl-2-fluoroadenine, and 9-β-D-arabinofuranosyladenine in human lymphoblastoid cells. Cancer Res 1980; 40: 2349–2355
   PubMed Web of Science ®Google Scholar
• White E L, Shaddix S C, Brockman R W, Bennett L L, Jr. Comparison of the actions of 9-β-d arabinofuranrjsyl-2-fluoroadenine, and 9-β-D-arabinofuranosyladenine on target enzymes from mouse tumor cells. Cancer Res 1982; 42: 2260–2264
   PubMed Web of Science ®Google Scholar
• Chang C H, Chen Y C. Effects of deoxyadenosine triphosphate and 9-β-D-arabinofuranosyladenine-5′triphosphate on human ribonucleotide reductase from Molt4-F cells and the concept of self-potentiation. Cancer Res 1980; 40: 3555–3558
   PubMed Web of Science ®Google Scholar
• Sato A, Montgomery J A, Cory J G. Synergistic inhibition of leukemia L1210 cell growth in vitro by combinations of 2-fluoroadenine nucleosides and hydroxyurea or 2,3-dihydro-lH-pyrazole [2,3-a]imidazole. Cancer Res 1984; 44: 3286–3290
   PubMed Web of Science ®Google Scholar
• Tseng W C, Derse D, Cheng Y C, et al. In vitro biological activity of 9-β-D-arabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells. Mol Pharmacol 1982; 21: 474–477
   PubMed Web of Science ®Google Scholar
• Avramis V I, Plunkett W. 2-Fluoro-ATP: A toxic metabolite of 9-β-D-arabinonosyl-2-fluoroadenine (F-araA). Biophys Biochem Res Comm 1983; 113: 35–43
   PubMed Web of Science ®Google Scholar
• Spriggs D, Robbins G, Mitchell T, Kufe D. Incorporation of 9-β-D-arabinofuranosyl-2-fluoroadenine into HL-60 cellular RNA and DNA. Biochem Pharmacol 1986; 35: 247–252
   PubMed Web of Science ®Google Scholar
• Huang P, Plunkett W. Preferential incorporation of arabinosyl-2-fluoroadenine (F-araA) into poly(A+) RNA and its inhibitory effects on transcription and translation. Proc Am Assoc Cancer Res 1986; 27: 21
   Web of Science ®Google Scholar
• Tavoussi M D, Avramis V I. Pharmacodynamics of fludarabine phosphate (F-araAMP) in P388 leukemia bearing mice after toxic and non-toxic regimens. Proc Am Soc Clin Oncol 1986; 5: 44
   Google Scholar
• Montgomery J A, Hewson K. Synthesis of potential anticancer agents, XX 2-fluoropurines. J Am Chem Soc 1960; 82: 463–468
   Web of Science ®Google Scholar
• Skipper H E, Schmidt L H, Goldin A, Venditti J M. A manual on quantitative drug evaluation in experimental tumor systems. Cancer Chemother Res 1962; 17: 1–178
   PubMedGoogle Scholar
• Schabel F J, Jr, Griswold D P, Laster W R, Jr, et al. Quantitative evaluation of anticancer agent activity in experimental animals. Pharmacol Ther A 1977; 1: 411–453
   Web of Science ®Google Scholar
• Plunkett W. Inhibition of adenosine deaminase to increase the antitumor activity of adenine nucleoside analogs. Ann NY Acad Sci 1985; 451: 150–159
   PubMed Web of Science ®Google Scholar
• Burton K. A study of the conditions and mechanisms of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid. Biochem J 1956; 62: 315–323
   PubMed Web of Science ®Google Scholar
• Avramis V I, Balis F M, Holcenberg J S, et al. Pharmacokinetics of arabinosyl-2-fluoroadenine (F-araA) in plasma and CSF of monkeys after F-araAMP administration. Proc Am Assoc Cancer Res 1986; 27: 407
   Web of Science ®Google Scholar
• Noker P E, Duncan G F, El Dareer S, Hill D L. Disposition of 9-β-D-arabinofuranosyl-2-fluoroadenine 5′-phosphate in mice and dogs. Cancer Treat Rep 1983; 67: 445–456
   PubMedGoogle Scholar
• Avramis V I, Alajajyan M, Huang S-H, Holcenberg J S. Deoxycytidine kinase (dCk) purification and characterization from CEM/0, CEM/dCk(-) and L1210/0 cells. Proc Am Assoc Cancer Res 1987; 28: 8
   Web of Science ®Google Scholar
• Struck R F, Shortnancy A T, Kirk M C, et al. Identification of metabolites of 9-β-D-arabinofuranosyl-2-fluoroadenine, an antitumor and antiviral agent. Biochem. Pharmacol 1982; 31: 1975–1978
   Web of Science ®Google Scholar
• Huyang P, Plunkett W. Phosphorolytic cleavage of 2-fluoroadenine from 9-β-D-arabinofuranosyl-2-fluoroadenine by Escherichia coli: A pathway for 2-fluoro-ATP production. Biochem Pharmacol 1987; 36: 2945–2950
   PubMed Web of Science ®Google Scholar
• Avramis V, Plunkett W. Effects of arabinosyl-2-fluoroadenine (F-araA) and its 5′-monophosphate (F-araAMP) in P388 leukemia bearing BDF, mice. Proc 13th Int Cancer Congress 1982; 553
   Google Scholar
• Avramis V, Plunkett W. 2-Fluoro-ATP: A new metabolite of arabinofuranosyl-2-fluoroadenine (F-araA). Fed Proc 1983; 43(3)361
   Google Scholar
• Zimmerman T P, Wolberg G, Duncan G S, et al. Inhibition of lymphocyte-mediated cytolysis by 2-fluoroadertosine evidence for 2-discrete mechanisms of drug action. Biochem Pharmacol 1978; 27: 1731–1737
   PubMed Web of Science ®Google Scholar